JP2009510064A - 神経障害、精神障害または疼痛性障害の処置用の新規化合物 - Google Patents

神経障害、精神障害または疼痛性障害の処置用の新規化合物 Download PDF

Info

Publication number
JP2009510064A
JP2009510064A JP2008533434A JP2008533434A JP2009510064A JP 2009510064 A JP2009510064 A JP 2009510064A JP 2008533434 A JP2008533434 A JP 2008533434A JP 2008533434 A JP2008533434 A JP 2008533434A JP 2009510064 A JP2009510064 A JP 2009510064A
Authority
JP
Japan
Prior art keywords
disease
pain
use according
disorder
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008533434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510064A5 (https=
Inventor
ミニディス，アレクサンダー
ウェンスボ，デイヴィッド
スラッシ，アブデルマリック
アイザック，メスヴィン
エリックソン，キャロライン
プロフィア，ベロニカ
バーグストロム，パー−オロブ
エドワーズ，ルイーズ
アロラ，ジャライ
ジン，タオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2009510064A publication Critical patent/JP2009510064A/ja
Publication of JP2009510064A5 publication Critical patent/JP2009510064A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
JP2008533434A 2005-09-29 2006-09-20 神経障害、精神障害または疼痛性障害の処置用の新規化合物 Pending JP2009510064A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72152705P 2005-09-29 2005-09-29
PCT/US2006/036423 WO2007040982A1 (en) 2005-09-29 2006-09-20 5- (phenylisoxazolylethoxy) -triazol- 3 -yl substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009211258A Division JP2010013476A (ja) 2005-09-29 2009-09-14 神経障害、精神障害または疼痛性障害の処置用の新規化合物

Publications (2)

Publication Number Publication Date
JP2009510064A true JP2009510064A (ja) 2009-03-12
JP2009510064A5 JP2009510064A5 (https=) 2009-11-05

Family

ID=37745801

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008533434A Pending JP2009510064A (ja) 2005-09-29 2006-09-20 神経障害、精神障害または疼痛性障害の処置用の新規化合物
JP2009211258A Pending JP2010013476A (ja) 2005-09-29 2009-09-14 神経障害、精神障害または疼痛性障害の処置用の新規化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009211258A Pending JP2010013476A (ja) 2005-09-29 2009-09-14 神経障害、精神障害または疼痛性障害の処置用の新規化合物

Country Status (18)

Country Link
US (4) US20080227824A1 (https=)
EP (1) EP1934209A1 (https=)
JP (2) JP2009510064A (https=)
KR (1) KR20080050421A (https=)
CN (1) CN101273037A (https=)
AR (1) AR058807A1 (https=)
AU (1) AU2006297462A1 (https=)
BR (1) BRPI0616228A2 (https=)
CA (1) CA2623009A1 (https=)
EC (1) ECSP088283A (https=)
IL (1) IL189990A0 (https=)
NO (1) NO20081434L (https=)
RU (1) RU2008108219A (https=)
TW (1) TW200800976A (https=)
UA (1) UA92503C2 (https=)
UY (1) UY29796A1 (https=)
WO (1) WO2007040982A1 (https=)
ZA (1) ZA200802163B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532869A (ja) * 2019-05-15 2022-07-20 スーリン、クラース 動物の疼痛の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン
JP2023501114A (ja) * 2019-11-05 2023-01-18 スーリン、クラース 哺乳動物の過労の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200821305A (en) * 2006-10-05 2008-05-16 Astrazeneca Ab MGluR5 modulators
BRPI0818448A2 (pt) * 2007-10-19 2015-05-12 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5.
TW200922585A (en) * 2007-10-26 2009-06-01 Astrazeneca Ab Amino 1,2,4-triazole derivatives as modulators of mGluR5
EP2324019A4 (en) * 2008-08-12 2011-10-05 Astrazeneca Ab CRYSTALLINE FORM OF (5- {(IR) -1- [5- (3-CHLOROPHENYL) ISOXAZOL-3-YL] ETHOXY} -4-METHYL-4H-L, 2, 4-TRIAZOL-3-YL) -PYRIDINE
WO2010019100A1 (en) * 2008-08-12 2010-02-18 Astrazeneca Ab A new crystalline form of 4- (5- { (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } -4-methyl-4h-l, 2, 4- triazol-3-yl) pyridine
CA2751761A1 (en) 2008-10-22 2010-04-29 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
BRPI0923215A2 (pt) * 2008-12-12 2017-06-06 Astrazeneca Ab método para fabricar um composto.
CA2747507A1 (en) * 2008-12-18 2010-06-24 Astrazeneca Ab New process for the preparation of 1- [5-(3-chloro-phenyl)-isooxazol-3-yl]-ethanone and (r)-1-[5-(3-chloro-phenyl)-isooxazol-3-yl]-ethanol
EP2379531A1 (en) * 2008-12-18 2011-10-26 AstraZeneca AB Processes for the manufacture of 3-{4-methyl-5- [ (ir) -1- (2- (3-methylphenyl) -2h-tetrazol-5-yl) -ethoxy]-4h- [1,2, 4]triazol-3-yl} -pyridine, 4-methyl-3-methylthio-5- (3- pyridyl)-l,2,4-triazole, and (ir) -1- [2- (3-methylphenyl) -2h- tetrazol-5-yl]ethanol
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CA2764339A1 (en) * 2009-06-05 2010-12-09 Oslo University Hospital Hf Azole derivatives as wtn pathway inhibitors
ES2443578T3 (es) 2009-12-29 2014-02-19 Eli Lilly And Company Compuestos de tetrahidrotriazolopiridina como potenciadores de receptores selectivos de mGlu5 útiles para el tratamiento de la esquizofrenia
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
UA112418C2 (uk) * 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
RU2013128448A (ru) 2010-12-08 2015-01-20 Осло Юниверсити Хоспитал Хф Производные триазола в качестве ингибиторов сигнального пути wnt
AU2012232711B2 (en) 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
WO2016163754A1 (en) * 2015-04-07 2016-10-13 Medpacto Inc. Pharmaceutical composition for preventing or treating cancer and method using thereof
KR20160120157A (ko) 2015-04-07 2016-10-17 주식회사 메드팩토 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
EP4525983A4 (en) 2022-05-16 2025-09-03 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS
EP4583872A1 (en) 2022-10-28 2025-07-16 Orphelion Ab Mglur5 receptor antagonists for use in prevention and/or treatment of bone marrow lesions (bml) and/or osteoporosis, cartilage loss, osteosclerosis, osteitis in a mammal

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100875222B1 (ko) 1999-08-19 2008-12-19 아스트라제네카 아베 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
MXPA03007513A (es) 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
US7074809B2 (en) 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
TW200424183A (en) 2002-08-09 2004-11-16 Nps Pharma Inc New compounds
WO2005060971A1 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
CA2548039A1 (en) 2003-12-19 2005-07-21 Astrazenca Ab 5-fluoro-, chloro- and cyano-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor-5
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
DE602005008558D1 (de) 2004-02-18 2008-09-11 Astrazeneca Ab Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
TW200531694A (en) 2004-02-18 2005-10-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
US20070185100A1 (en) 2004-02-18 2007-08-09 Astrazeneca Ab Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2005080356A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
RU2006127575A (ru) 2004-02-18 2008-03-27 Астразенека Аб (Se) Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"新医薬品の規格及び試験方法の設定について", 医薬審発第５６８号, JPN6010021254, 2001, ISSN: 0002248822 *
長瀬博監訳, 最新 創薬化学 下巻, JPN6008054607, 25 September 1999 (1999-09-25), JP, pages 347 - 365, ISSN: 0002248823 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532869A (ja) * 2019-05-15 2022-07-20 スーリン、クラース 動物の疼痛の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン
JP7444901B2 (ja) 2019-05-15 2024-03-06 スーリン、クラース 動物の疼痛の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン
JP2023501114A (ja) * 2019-11-05 2023-01-18 スーリン、クラース 哺乳動物の過労の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン
JP7579337B2 (ja) 2019-11-05 2024-11-07 スーリン、クラース 哺乳動物の過労の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン

Also Published As

Publication number Publication date
US20070270469A1 (en) 2007-11-22
BRPI0616228A2 (pt) 2011-06-14
ECSP088283A (es) 2008-04-28
US7476684B2 (en) 2009-01-13
AU2006297462A1 (en) 2007-04-12
UY29796A1 (es) 2007-04-30
US20070129408A1 (en) 2007-06-07
JP2010013476A (ja) 2010-01-21
RU2008108219A (ru) 2009-11-10
AR058807A1 (es) 2008-02-27
CA2623009A1 (en) 2007-04-12
ZA200802163B (en) 2009-09-30
CN101273037A (zh) 2008-09-24
NO20081434L (no) 2008-05-19
UA92503C2 (ru) 2010-11-10
WO2007040982A1 (en) 2007-04-12
EP1934209A1 (en) 2008-06-25
US20070270468A1 (en) 2007-11-22
US20080227824A1 (en) 2008-09-18
IL189990A0 (en) 2008-08-07
KR20080050421A (ko) 2008-06-05
TW200800976A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
JP2010013476A (ja) 神経障害、精神障害または疼痛性障害の処置用の新規化合物
JP2011500673A (ja) 代謝調節型グルタミン酸受容体（ｍｇｌｕｒｓ）の調節因子としてのテトラゾール誘導体
US20090111824A1 (en) Amide linked heteroaromatic derivatives as modulators of mglur5
JP2009536211A (ja) Ｍｇｌｕｒ５モジュレーターｉｉｉ
KR20090009952A (ko) Ｍｇｌｕｒ５ 조절제 ｉ
JP2007523181A (ja) ポリヘテロ環式化合物、および、代謝型グルタミン酸受容体アンタゴニストとしてのそれらの使用
KR20090060328A (ko) Ｍｇｌｕｒ５ 조절제
JP2009536214A (ja) 縮合複素環化合物及びｍｇｌｕｒ５モジュレーターとしてのその使用
JP2009536212A (ja) 多環式複素環化合物及び代謝調節型グルタミン酸５受容体の調節剤としてのその使用
JP2009536210A (ja) Ｍｇｌｕｒ５モジュレーターｉｉ
KR20100089091A (ko) Ｍｇｌｕｒ5의 조절제로서의 아미노 1,2,4-트리아졸 유도체
US20090111820A1 (en) Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
KR20030097886A (ko) 신규 피페리딘카르복스아미드 유도체, 이의 제조 방법 및이를 함유하는 제약 조성물
US20100273805A1 (en) Sulphide bridged derivatives as modulators of mglur5 733
US20090111823A1 (en) Aminopyridine derivatives as modulators of mglur5

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090914

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121130